Brady Zarina, Stoykova Zhivka
Medical University of Varna, Varna, Bulgaria.
Department of Microbiology and Virology, Medical Faculty, Medical University of Varna, Varna, Bulgaria.
J Drug Assess. 2019 Aug 8;8(1):146-149. doi: 10.1080/21556660.2019.1654484. eCollection 2019.
The main objective of this study was to analyse the spread of hepatitis C virus (HCV) genotype in patients with chronic liver disease; commenting on the molecular characterization of HCV and gender and age in Varna, Bulgaria. Across Europe and the world, HCV is a significant economic concern and public health crisis. Defined by genotype variations, HCV is the leading cause of chronic liver disease, liver related morbidity, and mortality worldwide. Active examination for asymptomatic patients is essential, initiating early treatment aimed at the specific HCV genotype, effective outcomes, and reducing transmission and mortality in Bulgaria. Nucleic acid extraction and amplification were performed with commercially available test kits on 115 patients blood samples collected from March 2018 to October 2018. Male ( = 58) (50.43%, 95% CI = 41.29%-59.57%) and female ( = 57) (49.57%, 95% CI = 41.29%-59.57%) samples were equally distributed (mean age = 51.4 years; SD = ±16.5 years; range = 17-87 years old). Genotype 1b predominated (73%, 95% CI = 64.89%-81.11%), followed by high prevalence of 1a (13.9%, 95% CI = 7.58%-20.22%) and 3 genotypes (11.3%, 95% CI = 5.51%-17.09%). Genotypes 2 and 4 were equally the least prevalent (0.9%, 95% CI = -0.83%-2.63%). In genotype 1b, 60.7% were women and 39.3% were men; in genotype 1a, 25% were women and 75% were men; and in genotype 3, only 7.7% were women and 92.3% were men. Males were most prevalent in genotypes 1a (75%) and 3 (92.3%), while women were most prevalent in genotype 1b (60.7%). HCV genotype lb is the predominant variant within the epidemiological pattern of HCV genotypes in patients with chronic liver diseases in North Eastern Bulgaria.
本研究的主要目的是分析丙型肝炎病毒(HCV)基因型在慢性肝病患者中的传播情况;对保加利亚瓦尔纳地区HCV的分子特征以及性别和年龄进行评论。在欧洲和全球范围内,HCV都是一个重大的经济问题和公共卫生危机。HCV由基因型变异定义,是全球慢性肝病、肝脏相关发病率和死亡率的主要原因。对无症状患者进行积极检查至关重要,在保加利亚要针对特定的HCV基因型启动早期治疗,以获得有效结果,并减少传播和死亡率。使用市售检测试剂盒对2018年3月至2018年10月收集的115例患者的血样进行核酸提取和扩增。男性(n = 58)(50.43%,95%置信区间 = 41.29% - 59.57%)和女性(n = 57)(49.57%,95%置信区间 = 41.29% - 59.57%)样本分布均匀(平均年龄 = 51.4岁;标准差 = ±16.5岁;范围 = 17 - 87岁)。基因型1b占主导(73%,95%置信区间 = 64.89% - 81.11%),其次是1a型(13.9%,95%置信区间 = 7.58% - 20.22%)和3型基因型(11.3%,95%置信区间 = 5.51% - 17.09%)流行率较高。基因型2和4的流行率同样最低(0.9%,95%置信区间 = -0.83% - 2.63%)。在基因型1b中,女性占60.7%,男性占39.3%;在基因型1a中,女性占25%,男性占75%;在基因型3中,女性仅占7.7%,男性占92.3%。男性在基因型1a(75%)和3型(92.3%)中最为常见,而女性在基因型1b(60.7%)中最为常见。HCV基因型1b是保加利亚东北部慢性肝病患者HCV基因型流行病学模式中的主要变异型。